Hormonal Therapy News and Research

RSS

Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.

11 Feb 2013

Partin Tables to predict prostate cancer spread now updated

Prostate cancer experts at Johns Hopkins have developed an updated version of the Partin Tables, a tool to help men diagnosed with prostate cancer and their doctors to better assess their chance of a surgical cure. The updated tool, based on a study of more than 5,600 men treated at The Johns Hopkins Hospital from 2006 to 2011, is published in the Jan. 3 issue of the British Journal of Urology International.

3 Jan 2013

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Reflexology can help cancer patients manage their symptoms and perform daily tasks

A study led by a Michigan State University researcher offers the strongest evidence yet that reflexology - a type of specialized foot massage practiced since the age of pharaohs - can help cancer patients manage their symptoms and perform daily tasks.

14 Nov 2012

Scientists identify biomarker associated with tamoxifen resistance in women with breast cancer

Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.

From The University of Manchester 3 Nov 2012

Elderly women with early-stage breast cancer live longer with radiation therapy and surgery

Elderly women with early-stage breast cancer live longer with radiation therapy and surgery compared with surgery alone, researchers at the University of Maryland School of Medicine have found.

30 Oct 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

Recurrent patterns of genomic imbalances determine evolution of invasive breast cancer

Ductal carcinoma in situ (DCIS) is considered a precursor lesion for invasive breast cancer if untreated, and is found in approximately 45% of patients with invasive ductal carcinoma (IDC). Patients with DCIS only (not accompanied by invasive disease) have a 5-year-survival of nearly 100%, compared to 89% for all stages of invasive breast cancer (24% for patients with distant metastasis).

17 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Four new studies on the treatment of early breast cancer

Four new studies on the treatment of early breast cancer, spanning from diagnosis through surgery, were released today in advance of the 2012 Breast Cancer Symposium.

13 Sep 2012

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

1 Sep 2012

Obesity at diagnosis of breast cancer associated with increased risk of recurrence

Extra pounds-even within the overweight but not obese range-are linked to a higher risk of recurrence of the most common type of breast cancer despite optimal cancer treatment, according to a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

27 Aug 2012

GTx reports revenue of $1.6 million for second quarter 2012

GTx, Inc. today provided a Company update and reported financial results for the second quarter of 2012.

8 Aug 2012

Combination hormonal therapy improves survival in advanced breast cancer

A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer.

2 Aug 2012

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

31 Jul 2012

IVF linked to increased relapse rate among MS patients

In vitro fertilisation (IVF) is linked to an increased rate of relapse among women with multiple sclerosis (MS), suggests a small study published online in the Journal of Neurology Neurosurgery and Psychiatry.

12 Jun 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

New medication proves effective in slowing the spread of metastatic prostate cancer

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

2 Jun 2012

New clinical trial to evaluate HSP90 inhibitor plus hormonal therapy for breast cancer

Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 (HSP90) has been shown to help malignant cells accommodate the genetic changes and profound disturbances in normal biology that occur in cancers.

23 May 2012

Combination of vaccine and letrozole effectively improves survival from breast cancer

A vaccine that targets cancer cells in combination with the drug letrozole, a standard hormonal therapy against breast cancer, significantly increased survival when tested in mice, a team of UC Davis investigators has found.

16 May 2012